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1 INTRODUCTION 
Diffuse large B cell lymphoma (DLBCL) is the 
most common type of lymphoma worldwide, 
accounting for nearly 30% of all lymphoid 
malignancies, and occurs in a broad age range 
with a median age of 70 years [1]. DLBCL is 
highly heterogeneous in immunophenotype, 
morphologic features, biologic performance and 
the response towards chemotherapy regimens 
[1]. To date, the aetiology of DLBCL is still largely 
unknown. Many research studies have been 
conducted on acquired modifications of genomic 
aberrations that may contribute to the 
pathogenesis of DLBCL. Amongst others these 
studies looked at the activation of the NF-kB 
pathway, translocation of BCL6 gene, TP53 
mutation and BCL2 gene alterations that have all 
been identified as common molecular 
dysregulations in DLBCL [2,3]. 
Lymphomagenesis does not only 
encompasses genomic alterations (such as 
mutations and single nucleotide polymorphism), 
but has also been shown to involve aberrant 
epigenetic-regulatory system. DNA methylation is 
a mechanism of epigenetic regulation of gene 
expression and its abnormality is believed to 
contribute significantly to the pathogenesis of 
lymphoma. Uniquely, DNA methylation involves 
no changes in the nucleotides and may be 
reversible [4]. Basically it is the addition of a 
methyl (CH3) group to the cytosine base of CpG 
islands typically in the promoter region which may 
then lead to silencing of the particular gene [5, 6]. 
Cytosine methylation mediated gene silencing is 
linked to the poor expression of tumour 
suppressor gene and certain growth-regulatory 
proteins in various lymphoid malignancies [5]. 
The numerous findings made related to 
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epigenetic gene silencing in cancers have led to 
the development of epigenetic biomarkers and 
targeted therapy [4].     
p16 gene on chromosome 9p21 is an 
important tumour suppressor gene involved in the 
p16/cyclin-dependent kinase (CDK) / 
retinoblastoma gene pathway of cell cycle control 
[7]. In addition to point mutations and deletion of 
p16, hypermethylation of promoter region of p16 
has been implicated in a wide range of 
malignancies including lymphomas [8,9]. In 
DLBCL particularly, a varying percentage of 
epigenetic inactivation of p16 promoter region 
was observed ranging from 16-54% [10]. 
Information in this area for Malaysia is still 
lacking. 
The most common type of assay used in 
DNA methylation study is methylation-specific 
PCR (MSP) following bisulfite treatment. It is 
sensitive and specific in detecting cytosine 
methylation in a CpG island [11]. Although it is a 
widely utilized and cost-effective method for 
determination of gene methylation status, the 
method does not quantify the degree of 
methylation at specific CpG sites [12,13,10]. 
Therefore, in order to allow for quantitative 
methylation analysis, several methods have been 
established. Methods that are capable of 
measuring the methylation level and pattern of 
either, a single CpG or few CpGs include High-
Resolution Melting (HRM) analysis, Combined 
Bisulfite Restriction Analysis (COBRA), Bisulfite 
Genomic Sequencing, Methylation Sensitive-
Single Nucleotide Primer Extension (MS-SNuPE), 
MethyLight and the recently established 
pyrosequencing technique [13].  
In this study, the PCR-based technique, 
pyrosequencing assay was used to quantitatively 
analyse p16 methylation in DLBCL samples, a 
sequencing-by-synthesis method that 
quantitatively evaluates the real-time 
incorporation of nucleotides through the 
enzymatic conversion of released pyrophosphate 
into a proportional light signal [14]. After bisulfite 
treatment and PCR, the degree of each 
methylation at each CpG position in a sequence 
is determined from the ratio of T and C [15,16, 
17]. Therefore, the aim of this study then was to 
examine p16 gene methylation in DLBCL tumour 
tissues using pyrosequencing assay. 
 
2 METHODOLOGY 
A total of 16 formalin-fixed paraffin-embedded 
(FFPE) lymphoma tissue blocks from patients 
diagnosed with DLBCL according to WHO 
classification were retrieved from Hospital Tengku 
Ampuan Afzan, Pahang and Hospital Universiti 
Sains Malaysia, Kelantan, of these six were 
females and 10 were males. The age range was 
27 to 84 years. The study was approved by the 
Ethics Committees from the International Islamic 
University Malaysia (IREC 170) and Universiti 
Sains Malaysia (USM/JEPeM/15100447).  
Genomic DNA was extracted from the 
tissue block sections using E.Z.N.A® FFPE DNA 
Omega Biotek kit as specified by the 
manufacturer. The purity and quantity of DNA 
was determined using NanoDrop 1000 (Thermo 
Scientific, US). DNA purity of the samples was 
measured as 260/280 ratio, and a ratio of ~1.8 
was accepted as purified dsDNA. The DNA 
samples were subsequently subjected to bisulfite 
treatment using EZ DNA Methylation-Lightning™ 
Kit (Zymo Research, Orange, CA) according to 
protocol stipulated by the manufacturer. In brief, 
200-500 ng of each DNA sample was incubated 
with Lightning Conversion reagent at 98°C for 8 
minutes and 54°C for 60 minutes. In a Zymo-
Spin™ IC Column, the solution was further 
incubated at room temperature for 20 minutes 
following the addition of L-Desulphonation Buffer. 
The bisulfite-treated DNA was subsequently 
eluted in a total volume of 20 µL. Sodium  
bisulfite converts unmethylated cytosine to  uracil 
while 5-methylcytosine remains unchanged  and 
it therefore  identifies  all  methylated  and  
unmethylated  CpG  positions  present  in  the 
genomic DNA [12]. 
The primers were designed using 
PyroMark Assay Design 2.0 software. The  
following primers were used for amplification of 
bisulfite-treated DNA targeting p16 promoter 
region: Forward 5’-
AGAGGATTTGAGGGATAGGG-3’, reverse  5’-
biotin-TACCTACTCTCCCCCTCT-3’. The 
amplicon length was 135 base pairs covering 7 
CpG positions (Figure 1a). The PCR reaction was 
performed in a final volume of 25µl, containing 
12.5 µl of PyroMark PCR Master Mix (1X), 2.5 µl 
of coral load, 5 µl of Q-solution, 0.75 µl of each 
forward and reverse primers (0.3 µM), 2 µl of 
bisulfite-treated DNA and 1.5 µl distilled water. 
The PCR cycling conditions were as follows: 
initial denaturation (95°C, 15 minutes); followed 
by 50 cycles of denaturation, annealing, and 
elongation at 94°C for 30 seconds, 57°C for 40 
seconds, and 72°C for 40 seconds respectively. 
The final extension step was done at 72°C for 10 
minutes.  
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Approximately 20 µl of the PCR product 
were immobilized on streptavidin-coated 
Sepharose beads (Streptavidin SepharoseTM 
High Performance, GE Healthcare, Sweden). The 
PCR products bound to the beads were purified 
and denatured into single-stranded DNA using 
PyroMark Q96 Vacuum Workstation according to 
the manufacturer’s instructions. The single-
stranded DNA templates were subsequently 
added to the annealing buffer containing 0.3µM of 
sequencing primer  
5’-GGTTGGTTGGTTATTAGA-3’.  
The sequence to be analysed was  
5’-GGGTGGGGYGGATYGYGTG YGTTYGGYG 
GTTGYGGAGAGGGGGAGAGTAGGTAG-3’. 
The sequencing reaction was accomplished by 
PyroMark Q96 ID (Qiagen) using the PyroMark® 
Gold Q96 Reagents (Qiagen). Triplicates were 
performed in samples with sufficient DNA. 
Protocol was performed until the pyrosequencer 
determined the results as PASS. The percentage 
of methylation was assigned to each of the CpG 
sites of each sample by evaluating the C/T ratio. 
The mean percentage of methylation was 
obtained for each of the analysed samples. SPSS 
version 12.0 was used to perform the statistical 
analysis. Spearman’s correlation analysis was 
used to find any correlation between mean 
methylation level of p16 with age and gender of 
patients. Significance level was set at 0.05. 
 
     Biotin-forward PCR pyro primer 
5’- AGAGGATTTGAGGGATAGGGTCGGAGGG 
GGTTTTTTCGTTAGTATCGGAGGAAGAAAGG 
AGGGGTTGGTGGTTATTAGAGGGTGGGGCG 
ATCGCGTGCGTTCGGCGGTTGCG 
GAGAGGGGAGAGTAGGTAGCGGGCGGCGG 
   Reverse PCR pyro primer 
    
Figure 1a. Schematic diagram of p16 promoter region 
(bisulfite-treated) analysed showing the starting points for 
PCR reactions of pyrosequencing. The shaded regions ‘C’ 
were the CpG sites analysed.  
 
3 RESULTS 
DLBCL tissues from 16 patients were evaluated 
for p16 methylation. Seven different CpG sites 
were assessed. The methylation level for DNA 
control set; unmethylated and methylated was 4% 
and 94%, respectively as shown in Table 1. All 
the 16 samples studied showed promoter 
methylation of p16. The range of mean 
methylation percentage was 18-81%. All samples 
except for ‘Sample ID 13’ (in which CpG 1 and 
CpG 3 sites showed absence of methylation) 
exhibited methylation of all the 7 CpG sites 
analysed. A representative pyrogram illustrating 
the methylation level detected in seven analysed 
CpGs within the p16 gene sequences is shown in 
Figure 1b. Using Spearman non-parametric 
correlation, there was no association between 
p16 mean methylation percentage and the age 
(p=0.83) and gender (p=0.29) of the patients 
(Table 2). 
 
Table 1. The methylation level of the seven CpG sites 
analysed in 16 samples by pyrosequencing assay. 
 
 
Sample 
ID 
 
Methylation level (%) 
CpG 
1 
CpG 
2 
CpG 
3 
CpG 
4 
CpG 
5 
CpG 
6 
CpG 
7 
Mean 
(±SD)  
 
1 12 15 22 25 21 16 18 18(5) 
2 4 21 21 37 19 16 22 20(10) 
3 8 28 20 41 25 26 26 25(10) 
4 18 28 37 42 44 26 25 31(10) 
5 20 42 33 41 41 34 28 34(8) 
6 15 42 15 38 41 38 48 34(13) 
7 25 38 34 49 37 35 32 36(7) 
8 47 50 45 44 45 45 44 46(2) 
9 39 55 43 58 56 51 54 51(7) 
10 29 54 48 70 66 53 50 53(13) 
11 46 69 48 63 70 58 61 59(9) 
12 49 75 63 87 91 59 55 68(16) 
13 0 100 0 94 100 92 100 69(48) 
14 51 81 63 84 81 65 65 70(12) 
15 71 86 68 81 82 79 82 78(7) 
16 26 96 53 96 100 93 100 81(29) 
 
Mean 
for each 
CpG 
 
28.7 
 
55 
 
38.3 
 
59.3 
 
57.4 
 
49.1 
 
50.6 
 
M 93 100 94 94 100 86 93 94(5) 
U 3 5 3 3 5 3 4 4(1) 
 
M = methylated control; U = unmethylated control. 
 
 
 
Table 2. Correlation between p16 methylation percentage and 
age and gender  
 
Characteristics Methylation percentage 
Age 
(27-84 years) 
0.83 
Gender 
Male (n=10) 
Female (n=6) 
 
0.29 
Significant correlation p<0.05 
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Figure 1b. Representative pyrogram for sample 4 showing quantification of methylation for 7 CpGs (shaded). 
 
4 DISCUSSION 
In this study, we examined the promoter 
methylation of p16 gene in sixteen archived 
specimens diagnosed with DLBCL using the 
pyrosequencing analysis, and to our knowledge, 
this is the first study done in Malaysia.  
Pyrosequencing is a PCR-based method. It 
quantifies the presence of gene methylation using 
small sized PCR products (100-150bp). This is 
considered an advantage particularly when the 
starting material is isolated genomic DNA 
obtained from archival samples such as FFPE 
tissues, as in the present work [14]. In the 
analysis of DNA methylation patterns, 
pyrosequencing reproducibly and accurately 
measure of degree of methylation at several 
CpGs in close proximity with high quantitative 
resolution [16].  
Our experience indicates that 
pyrosequencing is a simple method, cost effective 
and non-time consuming as the method can 
analyse 96 samples within a few hours (in a 
single assay). It reproducibly analyses both CpG 
rich and CpG poor regions [18]. Although we did 
not analyse any normal tissue, this method can 
be utilized to determine the threshold that 
discriminate DNA methylation in normal versus 
tumour tissues [18].  
We found that all our 16 DLBCL samples 
(100%) exhibited promoter methylation of p16. 
Though we were not able to analyse normal (non-
tumorous) samples for pyrosequencing and 
perform dilution series to validate our results, we 
have included 100% methylated and non-
methylated controls in the analysis, of which the 
quality has been validated by the manufacturing 
company. Previously, Zainuddin et.al [10] 
reported a lower percentage (37.2%) using the 
pyrosequencing assay. 
 
They however examined a larger number of 
cases (113) on four CpG sites. It has to be noted 
that the difference in methylation percentages 
was also due to the different CpG sites analyzed. 
Other methylation studies in DLBCL did not apply 
the pyrosequencing technology, hence a direct 
comparison on the similarities or differences of 
methylation percentages could not be made. On 
the other hand, using the qualitative method 
MSP, Yoon et.al [19] showed that 52% of their 
DLBCL cases harbour p16 methylation. 
Hypermethylation of p16 promoter was also 
demonstrated by Amara et.al [20] in 21 (46%) of 
46 DLBCL cases studied. Although MSP is a cost 
effective method to study DNA methylation, it is 
associated with high rate of false positives and 
several limitation in the analysis of CpG-poor 
regions with lack of ability to quantify the results, 
hence providing only information related to 
presence or absence of methylation [18].  
Shaw et al. [21] and Bihl et al. [7] have also 
utilized the pyrosequencing technology to 
determine the percentage of p16 methylation in 
different types of cancers, namely oral cancer 
and colorectal cancer. To be highlighted, the 
study conducted by Shaw et.al [21] showed that 
promoter methylation analysis using this method 
generated valuable quantitative data from several 
CpG sites as compared to qualitative data in 
MSP. Havik et al. [17] used both pyrosequencing 
and quantitative MSP methods to study MGMT 
methylation in gliomas and found that 
pyrosequencing is a better analytical method as 
well.  It has been established through many 
studies that epigenetic silencing of the tumor 
suppressor genes namely p16 gene is an 
important and common event in the pathogenesis 
of malignancies [22, 9]. It acts as an alternative 
mechanism to homozygous deletion and point 
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mutations in which it equally contributes to the 
loss of gene expression [8,23]. As p16 is involved 
in regulating the cell cycle through inhibition of 
kinase enzymes (CDK4 and CDK6) in order to 
control the progressive entry from G1 to S phase, 
transcriptionally silenced or lack of p16 has the 
potential to initiate inappropriate cell proliferation 
[9]. In aggressive lymphoma, lack of p16 protein 
in the absence of p16 gene deletions or 
mutations, and only cytosine methylation has 
been reported [24].  
Other studies have also demonstrated that 
inactivation of p16 epigenetically and loss of p16 
protein expression was common events in high-
grade B cell lymphoma and progression of low-
grade lymphoma into DLBCL [23,25]. DLBCL with 
hypermethylated p16 has been reported to 
commonly show a biologically aggressive 
phenotype and is associated with a worse 
prognosis [20]. There were also significant 
associations with B symptoms, high International 
Prognostic Index (IPI) scores, and advanced 
clinical stage [10, 20]. Though it is well-noted that 
the information on clinical stages of DLBCL is 
crucial particularly for survival analysis, we 
regrettably do not have complete information on 
stages for most of the samples. Moreover, this 
study has limited number of samples with high 
quality DNA for analysis. Nevertheless, the 
samples used in this study have been confirmed 
histologically to show >70% of cancer cells.  
The study has successfully utilized the 
pyrosequencing technology to identify promoter 
methylation of p16 in all 16 cases of DLBCL. 
However, the sample size utilized was limited, 
hence no correlation could be made with the 
clinical parameters. Since p16 methylation is a 
common event in our series of DLBCL cases, 
future studies should include a bigger sample 
size, clinicopathological information of the cases 
and analysis of the non-tumorous (normal) tissue. 
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